Clinical Trial Update: Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating afatinib in combination with chemotherapy for esophageal squamous cell carcinoma or lung squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Lung Squamous Cell Carcinoma

Drugs mentioned

• Gilotrif (Afatinib)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN